KEY DETAILS
Dailykos.com reports that the TRIUMPH-2 Phase III trial studied retatrutide, an experimental once-weekly injection being developed to treat obesity and type 2 diabetes.
AOL.com reports that retatrutide targets a Q1 2027 U.S. filing and anchors the bull case of $1,700 per share for Eli Lilly stock.
Fool.com reports that in a Phase 3 study conducted in China, olatorepatide led to a mean weight loss of up to 19% over 48 weeks.
Medscape.com reports that initial testing should include A1c and fasting glucose, creatinine and eGFR, liver enzymes, and a lipid profile.
Medicaldaily.com reports that out of 2,028,601 patients studied, about 7%, or 145,610, were taking a GLP-1 drug.
Dailykos.com reports that in the TRIUMPH-2 Phase III trial, people with a BMI of 35 or higher lost an average of 21.9% of their body weight on retatrutide's 12 mg dose after 80 weeks. AOL.com reports that retatrutide targets a Q1 2027 U.S. filing and anchors the bull case of $1,700 per share for Eli Lilly stock. Medicaldaily.com reports that in a study of outcomes after surgery among more than two million adults, about 7% were taking a GLP-1 drug.
Dailykos.com reports that the TRIUMPH-2 Phase III trial studied retatrutide, an experimental once-weekly injection being developed to treat obesity and type 2 diabetes. The outlet reports that 1,152 adults living with both obesity and type 2 diabetes took part over 80 weeks of injections. Dailykos.com reports that what sets retatrutide apart from semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors at once. The money side of that story is getting attention as well.
AOL.com reports that retatrutide targets a Q1 2027 U.S. filing and anchors the bull case of $1,700 per share for Eli Lilly stock. The outlet reports that in Q2, revenue rose 47.67% to $22.97 billion, beating the $20.69 billion estimate, while EPS of $8.38 exceeded the $6.58 forecast. AOL.com reports that management raised 2026 revenue guidance to $85 billion to $87 billion. The outlet also reports that Novo Nordisk's planned 50% Wegovy price cut in 2027 poses a risk, but Lilly's 60% volume growth already outpaces competitor pricing pressure, and that the 24/7 Wall St. price target for Eli Lilly is $1,478.22 over the next 12 months. Lilly isn't the only company in this market.
Fool.com reports that in a Phase 3 study conducted in China, olatorepatide led to a mean weight loss of up to 19% over 48 weeks. Fool.com names Regeneron Pharmaceuticals as one of the companies it highlights in the weight loss market. Fool.com also reports that in a Phase 2 study, trevogrumab, administered alongside Novo's semaglutide, led to lean mass preservation of up to 42.5% compared with just 7.3% in patients receiving semaglutide plus placebo. The outlet reports that in the second quarter, Regeneron's revenue increased by 17% year over year to $4.3 billion. Medscape.com also has guidance on lab work for patients on these drugs.
Medscape.com reports that initial testing should include A1c and fasting glucose, creatinine and estimated glomerular filtration rate, liver enzymes, and a lipid profile. The outlet reports that although GLP-1 drugs rarely harm the kidneys directly, dehydration can reduce kidney blood flow and trigger acute kidney injury, particularly when treatment starts or the dose increases, according to June 2026 clinical data. Medscape.com also reports that for patients with hypertension or type 2 diabetes, the American Diabetes Association also recommends a urine albumin-to-creatinine ratio to help detect early kidney stress. Another study looked at outcomes after surgery.
Medicaldaily.com reports that out of 2,028,601 patients studied, about 7%, or 145,610, were taking a GLP-1 drug. The outlet reports that after matching users with similar nonusers, GLP-1 use was linked with 11% lower odds of major cardiovascular complications, defined as heart attack, heart injury, stroke, or death. Medicaldaily.com reports that major heart-related complications occurred in 1.0% of GLP-1 users and 1.1% of nonusers, while postoperative infections occurred in 4.9% and 5.3%, according to figures reported by Newsweek.
You can find the full details on retatrutide's trial results and Eli Lilly's outlook at dailykos.com and aol.com, the olatorepatide, trevogrumab and Regeneron figures at fool.com, the lab testing guidance at medscape.com, and the surgical outcomes study at medicaldaily.com.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.